Medical Cannabis Advocacy in the United States During the 1960s

The legal landscape entering the 1960s

Cannabis entered the 1960s as a federally taxed and effectively prohibited substance under the Marihuana Tax Act of 1937 ^[1]. The drug had been removed from the United States Pharmacopoeia in 1942, ending its formal status as a recognized medicine ^[2]. Enforcement was aggressive: the Boggs Act (1951) and the Narcotic Control Act (1956) had established mandatory minimum sentences, including up to ten years for a first cannabis possession offense in some jurisdictions ^[3].

Medical use was not a live policy conversation at the start of the decade. Physicians who wanted to prescribe cannabis had no legal pathway, and the American Medical Association — which had actually opposed the 1937 Tax Act — had by the 1960s largely stopped defending cannabis as medicine ^[1].

The scientific turning point: Mechoulam and THC

The most consequential scientific event of the decade happened outside the United States. In 1964, Israeli chemists Raphael Mechoulam and Yechiel Gaoni at the Weizmann Institute isolated and characterized delta-9-tetrahydrocannabinol (THC) — the primary psychoactive constituent of cannabis ^[4] Strong evidence. Cannabidiol (CBD) had been isolated earlier (1940 by Adams; structure clarified by Mechoulam and Shvo in 1963), but the 1964 THC paper made rigorous pharmacology possible for the first time ^[5].

This mattered for advocacy because it converted cannabis from a botanical curiosity into a subject for standardized clinical research. U.S. investigators, including those at the National Institute of Mental Health, began funding controlled studies later in the decade, though almost all were focused on harms rather than therapeutic potential.

Counterculture, not medicine

Popular memory conflates 1960s cannabis activism with medical advocacy. It shouldn't. The visible movement — Allen Ginsberg's LEMAR (LEgalize MARijuana) committee founded in 1964, the 1967 'Human Be-In' in San Francisco, Ginsberg's essay 'The Great Marijuana Hoax' in the Atlantic Monthly (November 1966) — argued for adult recreational freedom on civil liberties grounds ^[6][7]. Medical claims were peripheral at best.

The cultural shift did, however, create political pressure. As middle-class college students were arrested in growing numbers, editorial boards and parents began questioning penalties that had previously been reserved, in public imagination, for jazz musicians and racial minorities ^[3][8].

Government commissions crack the consensus

Two federal-level events opened space for later medical reform. First, in 1967, President Lyndon Johnson's Commission on Law Enforcement and Administration of Justice released its report, which explicitly criticized the severity of cannabis penalties and noted that scientific evidence did not support treating cannabis like heroin ^[9]. Second, James L. Goddard, appointed FDA Commissioner in 1966, publicly stated that cannabis might be no more dangerous than alcohol — a remark that provoked congressional outrage but signaled internal government dissent ^[10].

Neither official action endorsed medical cannabis. But both undermined the 'no legitimate use' framing that had dominated since 1937, and both were cited repeatedly by later medical advocates.

The end of the decade: setting the stage

By 1969 the U.S. Supreme Court had struck down the Marihuana Tax Act in Leary v. United States, ruling that its registration requirement violated the Fifth Amendment ^[11]. Congress responded by drafting what became the Controlled Substances Act of 1970, which placed cannabis in Schedule I — the most restrictive category, reserved for substances with 'no currently accepted medical use.' That designation, made at the very end of the 1960s policy cycle, would become the central obstacle for medical cannabis advocates for the next half-century ^[12].

Also in 1970, attorney Keith Stroup founded the National Organization for the Reform of Marijuana Laws (NORML), an effort planned in the late 1960s ^[13]. NORML's initial platform was decriminalization, not medical use; the medical framing would develop later, driven by AIDS and cancer patients in the 1980s and 1990s.

Myths about the 1960s medical movement

Several persistent claims deserve correction.

• 'The medical marijuana movement started in the 1960s.' Disputed Organized medical cannabis advocacy is generally traced to Robert Randall's 1976 glaucoma case and the state-level therapeutic research programs of the late 1970s, not the 1960s ^[14].
• 'Doctors were prescribing cannabis in the 1960s.' No data There was no legal U.S. pathway for physician-prescribed cannabis in the 1960s. The federal Compassionate Investigational New Drug program did not begin until 1978.
• 'Nixon's commission recommended medical use.' Disputed The Shafer Commission (National Commission on Marihuana and Drug Abuse) reported in 1972, not the 1960s, and recommended decriminalization of personal use — not a medical program ^[15].

The honest history is that the 1960s produced the conditions for medical cannabis advocacy — a chemically defined active ingredient, cracks in federal consensus, and organized activists — without producing the movement itself.

Sources

How this page was made